IPO Boutique Research, Color & More Information for Subscribers
This content is restricted to IPO Boutique Subscribers Username or E-mail: Become a Subscriber Disclaimer IPO Boutique aggregates information on public companies and private companies, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual[…]
Place more than four decades of experience on your team. We use a combination of underwriter contacts, global sources and contacts at large institutional funds to provide the TRUEST picture of how an IPO is shaping up prior to its debut. We are on your team. Additionally, we provide comprehensive research to outline short and[…]
Place more than four decades of experience on your team. We use a combination of underwriter contacts, global sources and contacts at large institutional funds to provide the TRUEST picture of how an IPO is shaping up prior to its debut. We are on your team. Additionally, we provide comprehensive research to outline short and[…]
Place more than four decades of experience on your team. We use a combination of underwriter contacts, global sources and contacts at large institutional funds to provide the TRUEST picture of how an IPO is shaping up prior to its debut. We are on your team. Additionally, we provide comprehensive research to outline short and[…]
This past week eight IPOs debuted, zero updated terms and, at the time of this writing, ten new deals were filed. You can check out our latest report on the IPO pipeline by clicking here. Price sensitivity and a bit of pushback was the sentiment coming from the IPO market as four deals priced below[…]
IPO BOUTIQUE is one of the few syndicate services that provides ratings on all secondary offerings (Spots, blocks, marketed). We use our database of historical performances, underwriter trends and more than 40 years playing the syndicate service to give our clients a leg up. We meticulously keep records of our ratings. If interested please click below[…]
Optimism in the IPO market continues to reign as both deals that came to market had strong demand and equally as strong performance in the aftermarket. Rhythm Pharmaceuticals (Nasdaq: RYTM) upsized its offering and priced $1.00 above the range. ‘RYTM’ opened at $23.21 or 36.5% above its $17.00 offering price. Rhythm Pharmaceuticals traded as[…]
It was a very strong week for the IPO market as four of the seven IPOs opened with greater than a 10% premium at first trade. The best deal this week was the Zai Lab Limited (Nasdaq: ZLAB) offering. The offering upsized from 5.88mm shares to 8.0mm shares and priced at the high-end of[…]
It was another light week in the IPO market as just two IPOs came to market but both performed well in their respective debuts. Clementia Pharmaceuticals (Nasdaq: CMTA) priced at the high-end of its range, $15.00, and opened at $18.25 for a 21.7% gain at first trade. ‘CMTA’ hit a first week high of $18.95[…]
Four IPOs came to market including a strong debut from the second largest cash raise to debut in 2017. Altice USA (NYSE: ATUS) upsized its offering 37% and raised $1.91bn with a slightly above mid-range $30.00 pricing. ‘ATUS’ opened with a first trade of $31.60, or 5.3% above the offering price, and rallied in its[…]
SIGN UP FOR IPO BOUTIQUE’S FREE NEWSLETTER Two IPOs came to market this week with mixed success. Athenex Inc (Nasdaq: ATNX) priced a full-size deal at the low-end of the range, $11.00, and opened with a $1.00 premium at first trade. The heavily insider-backed offering traded well in its opening week as ‘ATNX’[…]
This past week two IPOs debuted, one IPO updated terms and two new deals were filed. Two IPOs came to market with far different levels of success. ShotSpotter, Inc (Nasdaq: SSTI) priced 2.8mm shares at the midpoint of the range, $11.00, and opened 10.9% higher with a first trade of $12.20. The Roth Capital underwritten[…]
This past week five IPOs debuted, zero updated terms and one new deal was filed. The trend in the IPO market continued as buy-side investors dictated pricings for new issues that came to the market. Of the five deals that debuted this past week, three priced below range and two priced at the low end[…]
This past week six IPOs debuted, four updated terms and six new deals were filed. There were seven IPOs on the schedule to debut this week and many of them were priced to the markets satisfaction and thus performed nicely. Four of the six deals that debuted priced within its initial range. The success this[…]
This past week zero IPOs debuted, ten updated terms and two new deals were filed. There were two IPOs on the schedule to debut this week, however, neither had the demand needed to successfully come to market. According to the underwriter, the Xtera Communications (Nasdaq: XCOM) deal has been pushed to next week. Please refer[…]
This past week two IPOs debuted, three updated terms and zero new deals were filed. Both IPOs that debuted this week came to market successfully but only after needing a severe price reduction. MyoKardia (Nasdaq: MYOK) priced its deal at $10.00—a whopping $5.00 below the initial $15-$17 range. The deal opened with a $1.08 premium[…]
This past week four IPOs debuted, one updated terms and ten new deals were filed. The week’s high profile deal, Ferrari N.V. (NYSE: RACE), was the only IPO of the four at opening to debut this week- that did not disappoint. Ferrari priced a full size deal at the high end of the range, $52,[…]
This past week five IPOs debuted, three updated terms and seven new deals were filed. Of the five deals that debuted this week, four needed to price significantly below their initial ranges in order to come to market. The single deal that was priced in-range, Pure Storage (NYSE: PSTG), opened $0.26 below its $17.00 IPO price[…]
This past week five IPOs debuted, five updated terms and two new deals were filed. Of the five deals that debuted this past week, two opened below their offering prices and one opened flat. Each deal that opened for trade, needed their terms adjusted to fit the buy-side bids. Edge Therapeutics (Nasdaq: EDGE) was the[…]
This past week five IPOs debuted, one updated terms and one new deal was filed. The two biotech deals that came to market were well-received by the IPO market. Aimmune Therapeutics (Nasdaq: AIMT) priced at the high end of the range, $16.00, and opened with a $1.50 premium. ‘AIMT’ traded as high as $27.00 on[…]